127 related articles for article (PubMed ID: 16496343)
21. A platform for designing HIV integrase inhibitors. Part 2: a two-metal binding model as a potential mechanism of HIV integrase inhibitors.
Kawasuji T; Fuji M; Yoshinaga T; Sato A; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8420-9. PubMed ID: 17005407
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity.
Di Santo R; Costi R; Artico M; Ragno R; Greco G; Novellino E; Marchand C; Pommier Y
Farmaco; 2005 May; 60(5):409-17. PubMed ID: 15910813
[TBL] [Abstract][Full Text] [Related]
23. Discovery of small molecule HIV-1 integrase dimerization inhibitors.
Tintori C; Demeulemeester J; Franchi L; Massa S; Debyser Z; Christ F; Botta M
Bioorg Med Chem Lett; 2012 May; 22(9):3109-14. PubMed ID: 22483582
[TBL] [Abstract][Full Text] [Related]
24. Development of integrase inhibitors for treatment of AIDS: an overview.
Dubey S; Satyanarayana YD; Lavania H
Eur J Med Chem; 2007 Sep; 42(9):1159-68. PubMed ID: 17367896
[TBL] [Abstract][Full Text] [Related]
25. Discovery of structurally diverse HIV-1 integrase inhibitors based on a chalcone pharmacophore.
Deng J; Sanchez T; Al-Mawsawi LQ; Dayam R; Yunes RA; Garofalo A; Bolger MB; Neamati N
Bioorg Med Chem; 2007 Jul; 15(14):4985-5002. PubMed ID: 17502148
[TBL] [Abstract][Full Text] [Related]
26. 4-Hydroxy-5-pyrrolinone-3-carboxamide HIV-1 integrase inhibitors.
Pace P; Spieser SA; Summa V
Bioorg Med Chem Lett; 2008 Jul; 18(14):3865-9. PubMed ID: 18595690
[TBL] [Abstract][Full Text] [Related]
27. Novel virtual screening protocol based on the combined use of molecular modeling and electron-ion interaction potential techniques to design HIV-1 integrase inhibitors.
Tintori C; Manetti F; Veljkovic N; Perovic V; Vercammen J; Hayes S; Massa S; Witvrouw M; Debyser Z; Veljkovic V; Botta M
J Chem Inf Model; 2007; 47(4):1536-44. PubMed ID: 17608406
[TBL] [Abstract][Full Text] [Related]
28. New developments in diketo-containing inhibitors of HIV-1 integrase.
Zhao G; Wang C; Liu C; Lou H
Mini Rev Med Chem; 2007 Jul; 7(7):707-25. PubMed ID: 17627583
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors.
Mustata GI; Brigo A; Briggs JM
Bioorg Med Chem Lett; 2004 Mar; 14(6):1447-54. PubMed ID: 15006380
[TBL] [Abstract][Full Text] [Related]
30. Integrase inhibitors for the treatment of HIV infection.
Pace P; Rowley M
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):471-9. PubMed ID: 18600564
[TBL] [Abstract][Full Text] [Related]
31. Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors.
Plewe MB; Butler SL; Dress KR; Hu Q; Johnson TW; Kuehler JE; Kuki A; Lam H; Liu W; Nowlin D; Peng Q; Rahavendran SV; Tanis SP; Tran KT; Wang H; Yang A; Zhang J
J Med Chem; 2009 Nov; 52(22):7211-9. PubMed ID: 19873974
[TBL] [Abstract][Full Text] [Related]
32. A platform for designing HIV integrase inhibitors. Part 1: 2-hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores.
Kawasuji T; Yoshinaga T; Sato A; Yodo M; Fujiwara T; Kiyama R
Bioorg Med Chem; 2006 Dec; 14(24):8430-45. PubMed ID: 17010623
[TBL] [Abstract][Full Text] [Related]
33. Amide-containing diketoacids as HIV-1 integrase inhibitors: synthesis, structure-activity relationship analysis, and biological activity.
Li H; Wang C; Sanchez T; Tan Y; Jiang C; Neamati N; Zhao G
Bioorg Med Chem; 2009 Apr; 17(7):2913-9. PubMed ID: 19269185
[TBL] [Abstract][Full Text] [Related]
34. Naphthoxazepine inhibitors of HIV-1 integrase: synthesis and biological evaluation.
Garofalo A; Grande F; Brizzi A; Aiello F; Dayam R; Neamati N
ChemMedChem; 2008 Jun; 3(6):986-90. PubMed ID: 18383063
[TBL] [Abstract][Full Text] [Related]
35. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
36. Investigation of the structural requirement for inhibiting HIV integrase: QSAR study.
Dessalew N
Acta Pharm; 2009 Mar; 59(1):31-43. PubMed ID: 19304556
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of purine derivatives incorporating metal chelating ligands as HIV integrase inhibitors.
Li X; Vince R
Bioorg Med Chem; 2006 Aug; 14(16):5742-55. PubMed ID: 16753300
[TBL] [Abstract][Full Text] [Related]
38. From ligand to complexes. Part 2. Remarks on human immunodeficiency virus type 1 integrase inhibition by beta-diketo acid metal complexes.
Bacchi A; Biemmi M; Carcelli M; Carta F; Compari C; Fisicaro E; Rogolino D; Sechi M; Sippel M; Sotriffer CA; Sanchez TW; Neamati N
J Med Chem; 2008 Nov; 51(22):7253-64. PubMed ID: 18983138
[TBL] [Abstract][Full Text] [Related]
39. Integration of human immunodeficiency virus as a target for antiretroviral therapy.
Semenova EA; Johnson AA; Marchand C; Pommier Y
Curr Opin HIV AIDS; 2006 Sep; 1(5):380-7. PubMed ID: 19372837
[TBL] [Abstract][Full Text] [Related]
40. Dissecting Tn5 transposition using HIV-1 integrase diketoacid inhibitors.
Czyz A; Stillmock KA; Hazuda DJ; Reznikoff WS
Biochemistry; 2007 Sep; 46(38):10776-89. PubMed ID: 17725323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
